Association Between Genetic Variants in TNF, IL6, and IL1B Genes and Severity of COVID-19: A Cross-Sectional Study of Patients from Southern Brazil.

Publication date: May 31, 2025

Background/Objectives: Genetic variants in cytokine genes such as IL1B, IL6, and TNF may influence inflammatory responses to SARS-CoV-2 and affect disease severity. This study investigates the role of these variants in relation to COVID-19 outcomes, including hospitalization, ICU admission, and mortality. Methods: A total of 500 unvaccinated individuals from southern Brazil diagnosed with COVID-19 via RT-PCR were analyzed. DNA was extracted from nasopharyngeal swabs and genotyped for functional variants selected based on evidence of regulatory function and prior associations with inflammatory outcomes-IL1B (rs4848306, rs1143623, rs16944, rs1143627), IL6 (rs1800795, rs2069832, rs2069840, rs2069845), and TNF (rs1799964, rs1800630, rs1799724, rs1800629, rs361525). Multivariate logistic regression analysis, adjusted for sex and age, was employed to assess the association between these genetic variants and severe clinical outcomes. Results: The results indicated that the IL1B rs16944-AG (OR: 1. 98 [95% CI: 1. 22-3. 23], p = 0. 006) and TNF rs1799964-CT (OR: 1. 97 [95% CI: 1. 22-3. 22], p = 0. 006) genotypes were associated with the need for hospitalization, while TNF rs1800630-AA (OR: 2. 37 [95% CI: 1. 08-5. 33], p = 0. 034) was associated with ICU admission. Additionally, the CC genotype of TNF rs1799964 was associated with a higher risk of mortality (OR: 3. 73 [95% CI: 1. 21-14. 37], p = 0. 034). Conclusions: Genetic variants-specifically IL1B rs16944 and rs1143627, and TNF rs1799964 and rs1800630-were associated with COVID-19 severity and should be further investigated in larger studies to evaluate their potential as predictive markers of severe outcomes in COVID-19.

Open Access PDF

Concepts Keywords
Brazil Brazilian population
Genetic disease severity
Hospitalization genetic polymorphisms
Inflammatory inflammatory response
Rs1800629 SARS-CoV-2

Semantics

Type Source Name
disease MESH acute respiratory distress syndrome
disease MESH hypoxemia
disease MESH dyspnea
disease MESH sore throat
disease IDO country
disease MESH severe acute respiratory syndrome
drug DRUGBANK Coenzyme M
drug DRUGBANK Ribostamycin
disease IDO role
disease MESH COVID-19
disease MESH respiratory failure
disease MESH pulmonary fibrosis
disease MESH death
disease MESH multiple organ failure
disease IDO production
disease MESH cytokine storm syndrome
disease MESH shock
disease MESH bronchial hyperreactivity
disease MESH septic arthritis
disease MESH COPD
disease MESH respiratory diseases
disease MESH syndromes
disease IDO host
disease IDO susceptibility
disease MESH complications
disease MESH Influenza
disease MESH heart diseases
disease MESH lung diseases
disease MESH obesity
disease MESH hematological diseases
disease MESH liver diseases
disease MESH asthma
pathway KEGG Asthma
disease MESH diabetes mellitus
disease MESH kidney diseases
disease IDO symptom
drug DRUGBANK Oxygen
disease MESH Inflammation
disease IDO immune response
drug DRUGBANK Adenine

Original Article

(Visited 1 times, 1 visits today)